Author

C. Seidman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 2 Assay:scRNA-seq· 2 Assay:ATAC-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Approach:deep learning· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1

Frequent Co-Authors

A. Bueno-Orovio· 1 shared A. Garfinkel· 1 shared B. N. Akerberg· 1 shared B. Rodriguez· 1 shared C. N. Toepfer· 1 shared C. Perez-Cervantes· 1 shared F. Lu· 1 shared F. Margara· 1 shared

Activity by Year

2022-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBioengineering

A. Bueno-Orovio

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Tbx5 maintains atrial identity by regulating an atrial enhancer network

M. E. Sweat, Y. Cao, X. Zhang, O. Burnicka-Turek, C. Perez-Cervantes, B. N. Akerberg, Q. Ma, H. Wakimoto, J. M. Gorham, M. K. Song, M. A. Trembley, P. Wang, F. Lu, M. Gianeselli, M. Prondzynski, , W. T. Pu

This study shows Tbx5 maintains atrial identity by regulating an atrial enhancer network through chromatin accessibility and looping.

bioRxiv · Apr 21, 2023Cell Biology

Human iPSC-CMs and in-silico technologies define mechanisms and accelerate targeted pharmacogenetics in hypertrophic cardiomyopathy

F. Margara, Y. Psaras, Z. J. Wang, M. Schmid, R. Doste, A. Garfinkel, G. G. Repetti, J. Seidman, C. Seidman, B. Rodriguez, C. N. Toepfer, A. Bueno-Orovio

The paper combines human iPSC-CMs and in-silico models to identify genotype-specific pathomechanisms and therapeutic targets in hypertrophic cardiomyopathy.

bioRxiv · Jun 8, 2022 · PreprintBioengineering